2-哌啶基噻唑 | 4175-70-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-哌啶基噻唑
• 中文别名: 环戊乙酸,3-氨基-3-羧基-,(1S-cis)-(9CI)
• 英文名称: 2-Piperidino-thiazol
• 英文别名: 1-(1,3-Thiazol-2-yl)piperidine；2-piperidin-1-yl-1,3-thiazole
• CAS: 4175-70-6
• 化学式: C₈H₁₂N₂S
• mdl: MFCD00234458
• 分子量: 168.263
• InChiKey: XSHHZEANTJNOHO-UHFFFAOYSA-N

物化性质

• 沸点：
  270℃
• 密度：
  1.165
• 闪点：
  117℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  44.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934100090
• 储存条件：
  存储温度：2-8°C，密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Piperidinothiazole
Synonyms: 1-(1,3-Thiazol-2-yl)piperidine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Piperidinothiazole
CAS number: 4175-70-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H12N2S
Molecular weight: 168.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-哌啶基噻唑 在 硫酸 、 硝酸 作用下， 生成 5-Nitro-2-piperidino-thiazol
  参考文献：
  名称：

  Friedmann,A.; Metzger,J., Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques, 1969, vol. 269, p. 1000 - 1001

  摘要：

  DOI：
• 作为产物：
  描述：

  哌啶 、 2-氯噻唑 在 C₅₀H₆₁Cl₂N₃Pd 、 potassium tert-butylate 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以95%的产率得到2-哌啶基噻唑
  参考文献：
  名称：

  PD-PEPPSI-IPent一种推荐芳基氯化物的失活与胺化在有氧条件下的胺

  摘要：

  我们在此报告了一种由“大体积但还灵活”的Pd-PEPPSI-IPent An复合物进行的高效Pd催化胺化反应。讨论了N-杂环卡宾（NHCs）结构与催化性能之间的关系。可以在该交叉偶联中应用立体受阻的（杂）芳基氯化物以及各种脂肪族和芳香族胺，它们可以顺利进行以提供所需的产物。操作简单的协议强调了在不排除空气和水分的情况下，在温和条件下可快速获得C Ar -N键的形成。

  DOI：

  10.1021/acs.joc.8b01205

文献信息

• [EN] N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE<br/>[FR] DÉRIVÉS N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-MÉTHYLPROPIONYL)-PIPÉRIDINE EN TANT QU'INHIBITEURS DE PYRUVATE DÉSHYDROGÉNASE KINASE
  申请人：MERCK PATENT GMBH

  公开号：WO2015090496A1

  公开（公告）日：2015-06-25

  Compounds of the formula (I) in which R, R1 and R3 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

  公式(I)中的化合物，其中R、R1和R3的含义如权利要求1所述，是丙酮酸脱氢酶激酶（PDHK）的抑制剂，可以用于治疗诸如癌症等疾病。
• [EN] NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVELLES TÉTRAHYDROPYRIDOPYRIMIDINES ET TÉTRAHYDROPYRIDOPYRIDINES POUR LE TRAITEMENT ET LA PRÉVENTION D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016107832A1

  公开（公告）日：2016-07-07

  The invention provides novel compounds having the general formula (I): wherein R1, R2, R3, Q, U,W, Z, X and Y are as described herein, compositions including the compounds and methods of using the compounds. These compounds are HbsAg inhibitors and are useful as medicaments for the treatment or prophylaxis of HBV infection.

  这项发明提供了具有一般式（I）的新化合物：其中R1、R2、R3、Q、U、W、Z、X和Y如本文所述，包括这些化合物的组合物以及使用这些化合物的方法。这些化合物是HbsAg抑制剂，可用作治疗或预防HBV感染的药物。
• [EN] THIAZOLYLPIPERIDINE DERIVATIVES AS MTP INHIBITORS<br/>[FR] DERIVES DE LA THIAZOLYLPIPERIDINE, INHIBITEURS DE LA MTP
  申请人：MERCK PATENT GMBH

  公开号：WO2005003128A1

  公开（公告）日：2005-01-13

  The present invention relates to thiazolylpiperidine derivatives of the gen­eral formula (I): in which: A represents a radical chosen from the radicals a1 and a2 below: G represents a bond or a divalent radical chosen from the groups g1, g2 and g3 below: and R1, R2, R2’, R3, R4, R5, Y and Z are as defined in the description. Application of the compounds of the formula (I) to the treatment of hyper­triglyceridaemia, hypercholesterolaemia and dyslipidaemia.

  本发明涉及通式（I）的噻唑基哌啶衍生物：其中：A代表从下述a1和a2基团中选择的一个基团：G代表一个键或从下述g1、g2和g3组中选择的一个二价基团：且R1、R2、R2'、R3、R4、R5、Y和Z按描述定义。将公式（I）的化合物应用于治疗高甘油三酯血症、高胆固醇血症和血脂异常。
• [EN] HIV INHIBITORS<br/>[FR] INHIBITEURS DU VIH
  申请人：NEW YORK BLOOD CT INC

  公开号：WO2013036676A1

  公开（公告）日：2013-03-14

  Chemical compounds that inhibit retroviruses are presented herein. More particularly, this disclosure provides small molecule compounds that inhibit infection with, or treat infection caused by, human immunodeficiency viruses.

  本文介绍了抑制逆转录病毒的化合物。更具体地，本公开提供了抑制感染人类免疫缺陷病毒或治疗由其引起的感染的小分子化合物。
• INHIBITORS OF SPHINGOSINE KINASE
  申请人：Stieber Frank

  公开号：US20120252815A1

  公开（公告）日：2012-10-04

  The present invention relates to compounds of the formula (I), in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , M 1 , M 2 , M 3 , Y 1 , Y 2 , V, W, n, m and o have the gleanings given herein, and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use in the treatment of diseases which are influenced by inhibition of Sph kinase 1.

  本发明涉及化合物的结构式(I)，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、M1、M2、M3、Y1、Y2、V、W、n、m和o具有此处所述的含义，以及其生理上可接受的盐、衍生物、前药、溶剂化合物、互变异构体和立体异构体，包括所有比例的混合物，用于治疗受Sph激酶1抑制影响的疾病。